EP1915369A4 - Novel substituted 1,2,3-t ii azolylmethyl-benzothiophene or -indole and their use as leukotiiene biosynthesis inhibitors - Google Patents

Novel substituted 1,2,3-t ii azolylmethyl-benzothiophene or -indole and their use as leukotiiene biosynthesis inhibitors

Info

Publication number
EP1915369A4
EP1915369A4 EP06775086A EP06775086A EP1915369A4 EP 1915369 A4 EP1915369 A4 EP 1915369A4 EP 06775086 A EP06775086 A EP 06775086A EP 06775086 A EP06775086 A EP 06775086A EP 1915369 A4 EP1915369 A4 EP 1915369A4
Authority
EP
European Patent Office
Prior art keywords
leukotiiene
azolylmethyl
benzothiophene
indole
biosynthesis inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06775086A
Other languages
German (de)
French (fr)
Other versions
EP1915369A1 (en
Inventor
Carl Berthelette
Claude Dufresne
Lianhai Li
Zhaoyin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of EP1915369A1 publication Critical patent/EP1915369A1/en
Publication of EP1915369A4 publication Critical patent/EP1915369A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP06775086A 2005-08-11 2006-08-08 Novel substituted 1,2,3-t ii azolylmethyl-benzothiophene or -indole and their use as leukotiiene biosynthesis inhibitors Withdrawn EP1915369A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70736205P 2005-08-11 2005-08-11
PCT/CA2006/001306 WO2007016784A1 (en) 2005-08-11 2006-08-08 Novel substituted 1,2,3-tπazolylmethyl-benzothiophene or -indole and their use as leukotπene biosynthesis inhibitors

Publications (2)

Publication Number Publication Date
EP1915369A1 EP1915369A1 (en) 2008-04-30
EP1915369A4 true EP1915369A4 (en) 2010-09-08

Family

ID=37727061

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06775086A Withdrawn EP1915369A4 (en) 2005-08-11 2006-08-08 Novel substituted 1,2,3-t ii azolylmethyl-benzothiophene or -indole and their use as leukotiiene biosynthesis inhibitors

Country Status (5)

Country Link
EP (1) EP1915369A4 (en)
JP (1) JP2009504575A (en)
AU (1) AU2006279211A1 (en)
CA (1) CA2618586A1 (en)
WO (1) WO2007016784A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065093A1 (en) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd PHARMACEUTICAL COMPOUNDS INHIBITING THE BIOSYNTHESIS OF LEUCOTRIENS
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
JP2014508111A (en) 2010-12-07 2014-04-03 アミラ ファーマシューティカルス，インコーポレーテッド Lysophosphatidic acid receptor antagonist, its use in the treatment of fibrosis
LT2648726T (en) 2010-12-07 2018-06-25 Amira Pharmaceuticals, Inc. Polycyclic lpa1 antagonist and uses thereof
JP2014513077A (en) 2011-04-05 2014-05-29 アミラ ファーマシューティカルス，インコーポレーテッド Compounds based on 3- or 5-biphenyl-4-ylisoxazole useful for the treatment of fibrosis, pain, cancer, and respiratory, allergic, nervous system or cardiovascular disease
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
CA2977947A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
EP4052707A1 (en) 2016-09-07 2022-09-07 Pharmakea, Inc. Uses of a lysyl oxidase-like 2 inhibitor
BR112019004517A2 (en) 2016-09-07 2019-08-13 Pharmakea Inc crystalline forms of a lysyl oxidase-like inhibitor 2 and preparation methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (en) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Imidazole, triazole and tetrazole derivatives, method of producing same, their use and pharmaceutical compositons on their base
AU2004245146B2 (en) * 2003-06-11 2010-01-21 Merck Frosst Canada Ltd 7-(1,3-thiazol-2-yl)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO2007016784A1 *

Also Published As

Publication number Publication date
CA2618586A1 (en) 2007-02-15
AU2006279211A1 (en) 2007-02-15
JP2009504575A (en) 2009-02-05
WO2007016784A1 (en) 2007-02-15
EP1915369A1 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
TWI369351B (en) 2,4-diamino-pyrimidines as aurora inhibitors
EP1915369A4 (en) Novel substituted 1,2,3-t ii azolylmethyl-benzothiophene or -indole and their use as leukotiiene biosynthesis inhibitors
IL184901A0 (en) 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
PL1928840T3 (en) 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors
IL192053A0 (en) 2-adamantylurea derivatives as selective 11??-hsd1 inhibitors
GB0505970D0 (en) Culture medium containing kinase inhibitor, and uses thereof
IL191711A0 (en) 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors
IL184524A0 (en) Substituted pyrazolo-pyridines, compositions containing them, method for the production thereof, and their use
IL185185A0 (en) Azolylacylguanidines as ??-secretase inhibitors
EP1951680A4 (en) Novel 2-aminopyrimidinone derivatives and their use
IL187790A0 (en) Fk 228 derivatives as hdac inhibitors
ZA200810640B (en) 1,5 -Diphenylpyrazoles II as HSP90 Inhibitors
AU2006321904A8 (en) 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors
EP1946764A4 (en) Nutrient composition
EP1962852A4 (en) Compounds, compositions and methods
EP1951682A4 (en) Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use
PL378587A1 (en) Methods of (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazole and/or its salts
IL189112A0 (en) NOVEL HETEROCYCLIC NF-kB INHIBITORS
GB0513888D0 (en) Core 2 GLCNAC-T Inhibitors II
EP1908786A4 (en) 2-cyanoacrylate composition
ZA200706672B (en) 2,4-Diamino-pyridopyrimidine derivatives and their use as mTOR inhibitors
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
HK1115878A1 (en) (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors
EP1898940A4 (en) Inhibitors of the alpha2beta 1/gpia-iia integrin
GB0516245D0 (en) Process, composition and compound

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080311

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100810

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110308